Julian Baker’s Chinook Therapeutics, Inc. Common Stock KDNY Stock Holding History

Julian Baker’s Portfolio KDNY Stock Details KDNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-1,455,202	Closed	-$55.9M	–	114
2023 Q2	$55.9M	Hold	1,455,202	–	–	0.32%	22
2023 Q1	$33.7M	Sell	1,455,202 -1,078,900	-43%	-$25.7M	0.18%	29
2022 Q4	$66.4M	Hold	2,534,102	–	–	0.4%	18
2022 Q3	$49.8M	Hold	2,534,102	–	–	0.33%	27
2022 Q2	$44.3M	Buy	2,534,102 +200,000	+9%	+$3.14M	0.25%	28
2022 Q1	$38.2M	Hold	2,334,102	–	–	0.22%	36
2021 Q4	$38.1M	Buy	2,334,102 +431,033	+23%	+$6.14M	0.19%	41
2021 Q3	$24.3M	Buy	1,903,069 +822,676	+76%	+$10.8M	0.11%	57
2021 Q2	$15.3M	Buy	1,080,393 +331,700	+44%	+$5.31M	0.07%	68
2021 Q1	$11.6M	Hold	748,693	–	–	0.05%	72
2020 Q4	$11.9M	Buy	+748,693	New	+$11.3M	0.04%	69

Julian Baker's KDNY Position: Q3 2023 in Review

Julian Baker sold out of Chinook Therapeutics, Inc. Common Stock (KDNY) in Q3 2023, closing a stake of 1,455,202 shares — an estimated $55.9M sold.

Julian Baker first reported a position in KDNY in Q4 2020 and held it in 11 quarters. The position peaked at $66.4M in Q4 2022. 2 funds tracked by Wall St. Rank hold KDNY as of Q3 2023.

Julian Baker reported no remaining Chinook Therapeutics, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
Julian Baker sold 1,455,202 Chinook Therapeutics, Inc. Common Stock shares in Q3 2023, an estimated $55.9M.
Julian Baker first reported a position in Chinook Therapeutics, Inc. Common Stock in Q4 2020 and held it in 11 quarters.
Julian Baker's Chinook Therapeutics, Inc. Common Stock position peaked at $66.4M in Q4 2022.
2 funds tracked by Wall St. Rank held Chinook Therapeutics, Inc. Common Stock as of Q3 2023.

Based on Baker Bros. Advisors's 13F filing for Q3 2023, filed 14 Nov 2023.